At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 580 enrolled
Drug / intervention
ABT-450 +4 moredrug
Likely dose
Ribavirin 1,200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
In Brief
A Phase 2 clinical trial evaluating ABT-450, ABT-333, and 3 other interventions for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 580 participants across 97 sites in 9 countries.
Detailed Summary
This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedNov 2011
Primary CompletionMar 2013
Study CompletionSep 2013
TodayJul 2026
First PostedNov 4, 2011
Enrollment StartOct 1, 2011
Primary CompletionMar 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.7 years ago
Interventions
ABT-450drug
ABT-450 tablets
ABT-333drug
ABT-333 tablets
ABT-267drug
ABT-267 tablets
Ribavirindrug
Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
Ritonavirdrug
Ritonavir capsules